Effects of different oxygen therapy methods on blood gas analysis,cardiac function,and coagulation function indicators in patients with pulmonary heart disease complicated by type Ⅱ respiratory failure
Objective To explore the effects of high-flow nasal cannula(HFNC)oxygen therapy and low-flow nasal cannula oxygen therapy on blood gas analysis,cardiac function,and coagulation function indicators in patients with pulmonary heart disease(PHD)complicated by type Ⅱ respiratory failure,aiming to provide a reference for treatment options for these pa-tients.Methods From January 2022 to June 2023,patients with PHD complicated by type Ⅱ respiratory failure treated at the People's Hospital of Aba Tibetan and Qiang Autonomous Prefecture were randomly divided into observation and control groups,with 67 patients in each.The control group received low-flow nasal cannula oxygen therapy,while the observation group received HFNC therapy.The clinical efficacy,pre-and post-treatment blood gas indices[pulse oxygen saturation(SpO2),arterial partial pressure of oxygen(PaO2),arterial partial pressure of carbon dioxide(PaCO2)],coagulation func-tion indices[prothrombin time(PT),activated partial thromboplastin time(APTT),fibrinogen(Fg),D-dimer(D-D)],cardiac function indices[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),brain natriuretic peptide(BNP)],pulmonary function indices[forced expiratory volume in 1 second(FEV1),forced vital capacity(FVC),peak expiratory flow(PEF)],and inflammation markers,including C-reactive protein(CRP)and procalcitonin(PCT),were compared between the two groups.Results The overall treatment efficacy rate in the observation group was 92.54％(62/67),which was significantly higher than the 77.61％(52/67)observed in the control group(x2=5.877,P=0.015).Before treatment,no significant differences were noted between the two groups in SpO2,PaO2,and PaCO2 levels(P＞0.05).After treatment,both groups showed improvements in SpO2 and PaO2 levels,with the observation group showing significantly higher levels compared to the control group,and a decrease in PaCO2 levels,with the observation group showing significantly lower levels than the control group(P＜0.05).Before treatment,no significant differences were observed between the two groups in PT,APTT,Fg,and D-D levels(P＞0.05).After treatment,PT and APTT lev-els were higher in both groups compared to pre-treatment levels,with the observation group showing significantly higher levels than the control group;Fg and D-D levels were lower in both groups compared to pre-treatment levels,with the ob-servation group showing significantly lower levels than the control group(P＜0.05).Before treatment,no significant differences were found in LVESD,LVEF,and BNP levels between the two groups(P＞0.05).After treatment,LVEF levels were higher in both groups compared to pre-treatment levels,with the observation group showing significantly higher levels than the control group;BNP levels were lower in both groups compared to pre-treatment levels,with the observation group showing significantly lower levels than the control group;LVESD levels were smaller in both groups compared to pre-treatment levels,with the observation group showing significantly lower levels than the control group(P＜0.05).Before treatment,no significant differences were noted between the two groups in FEV1,FVC,and PEF levels(P＞0.05).After treatment,FEV1,FVC,and PEF levels were higher in both groups compared to pre-treatment levels,with the observation group showing significantly higher levels than the control group(P＜0.05).Before treatment,no significant differences were observed in CRP and PCT levels between the two groups(P＞0.05).After treatment,CRP and PCT levels were low-er in both groups compared to pre-treatment levels,with the observation group showing significantly lower levels than the control group(P＜0.05).Conclusion For patients with PHD complicated by type Ⅱ respiratory failure,HFNC therapy provides superior clinical efficacy,improving blood gas indices,cardiac function,and coagulation function more effectively than low-flow nasal cannula oxygen therapy.
Pulmonary heart diseaseType Ⅱ respiratory failureHigh-flow nasal cannula oxygen therapyLow-flow nasal cannula oxygen therapyCardiac functionBlood gas indicesPulmonary function
万方数据
维普
